Q2 2026 saw 11% reported and 6% organic sales growth, with strong Prosthetics & Neuro Orthotics performance and improved profitability. Net profit rose 39% year-over-year, and guidance for full-year organic sales growth was narrowed to 5-7% with EBITDA margin maintained at 20-22%.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.